STSA News and Press, Satsuma Pharmaceuticals Inc. From 03/28/23

- Announced topline results from STS101 SUMMIT Phase 3 efficacy trial that the company believes demonstrate STS101 provides differentiated, robust and sustained anti-migraine effects - - Submitted STS101 New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) in March 2023...

SOUTH SAN FRANCISCO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of mi...

Further analysis of results from recently-completed SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine shows differentiating robust and sustained antimigraine effects on clinically important secondary endpoints Qualitative and quantitative primary market researc...

Want To Find Penny Stocks to Buy? You Might Want To Follow The Money Whether you’re talking about penny stocks or not, everyone wants an edge over the rest of the market. We’ll discuss the “Follow The Money” strategy today. It’s not overly complica...

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment...

Hot Penny Stocks For Your November Watch List unlike what popular opinion might suggest, penny stocks aren’t just fly-by-night companies to treat like a roulette table bet. These cheap stocks have gained so much attention this year thanks to the 2022 stock market sell-off. In ple...

Mizuho has downgraded Satsuma Pharmaceuticals ( NASDAQ: STSA ) to neutral from buy after migraine therapy STS101 failed in a phase 3 trial . The firm also lowered its price target to $2 from $14 (194% upside based on Monday's close). The stock is down ~7% in Tu...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Iryna Imago / Shutterstock.com The focus in the world of drugmakers is on Satsuma Pharmaceuticals (NASDAQ: STSA ) right now, but not in a good way. Specifically, the company’s proposed treatment for m...

Satsuma Pharmaceuticals ( NASDAQ: STSA ) migraine therapy STS101 did not meet the main goals of a phase 3 trial and the company said it does not plan to invest in commercializing STS101 and will explore alternatives to maximize value and cut cash expenditures. STS101 is ...

STS101 was not statistically superior to placebo at two hours post-administration on the co-primary endpoints of freedom from pain and most bothersome symptom STS101 showed superiority (p<0.001) differences versus placebo on freedom from pain and most bothersome symptom at al...